Patents by Inventor John Ryan Kerrigan

John Ryan Kerrigan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12103919
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: October 1, 2024
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Janetta Dewhurst, John Ryan Kerrigan, Gary O'Brien, MooJe Sung, Noel Marie-France Thomsen, Pamela Ting
  • Publication number: 20240158374
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: September 1, 2023
    Publication date: May 16, 2024
    Inventors: Simone BONAZZI, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie Alysia DALES, Janetta DEWHURST, Matthew James HESSE, Rama JAIN, John Ryan KERRIGAN, Hasnain Ahmed MALIK, James R. MANNING, Gary O'BRIEN, Andrew W. PATTERSON, Noel Marie-France THOMSEN, Pamela YF TING
  • Patent number: 11787785
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 17, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Y F Ting
  • Publication number: 20230279394
    Abstract: The present invention is directed to compositions and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: December 16, 2020
    Publication date: September 7, 2023
    Inventors: Muluken BELEW, Simone BONAZZI, James BRADNER, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Carsten RUSS, Frederic SIGOILLOT, Susan C. STEVENSON, Noel Marie-France THOMSEN, Pamela TING
  • Publication number: 20230108325
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: March 14, 2022
    Publication date: April 6, 2023
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela YF TING
  • Patent number: 11566022
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders, including hemoglobinopathies, sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Dales, John Ryan Kerrigan, Philip Lam, Hasnain Ahmed Malik, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Ting
  • Publication number: 20230019617
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: June 1, 2022
    Publication date: January 19, 2023
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Janetta Dewhurst, John Ryan Kerrigan, Gary O'Brien, MooJe Sung, Noel Marie-France Thomsen, Pamela Ting
  • Publication number: 20220402904
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: December 16, 2020
    Publication date: December 22, 2022
    Inventors: Simone BONAZZI, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Gary O'BRIEN, Andrew W. PATTERSON, Noel Marie-France THOMSEN, Pamela TING
  • Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • Patent number: 10654828
    Abstract: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 19, 2020
    Assignee: NOVARTIS AG
    Inventors: John Ryan Kerrigan, Natalie Dales, George Scott Tria, Daniel Palacios, Paul Gormisky
  • Patent number: 10633350
    Abstract: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 28, 2020
    Assignee: NOVARTIS AG
    Inventors: Natalie Dales, Paul Gormisky, John Ryan Kerrigan, Lei Shu
  • Publication number: 20190077773
    Abstract: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 12, 2018
    Publication date: March 14, 2019
    Inventors: Natalie DALES, Paul GORMISKY, John Ryan KERRIGAN, Lei SHU
  • Publication number: 20190055219
    Abstract: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: July 26, 2018
    Publication date: February 21, 2019
    Applicant: NOVARTIS AG
    Inventors: John Ryan Kerrigan, Natalie Dales, George Scott Tria, Daniel Palacios, Paul Gormisky